Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Mar
10
Today In Oncology
Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
AI-Backed Liquid Biopsies Identify Liver Diseases
Peter WT Pisters Honored With Top Award From Society of Surgical Oncology
TACE With Camrelizumab and Rivoceranib in Unresectable Hepatocellular Carcinoma
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo